India Biopharmaceutical Cmo And Cro Market Size & Outlook
Related Markets
India biopharmaceutical cmo and cro market highlights
- The India biopharmaceutical cmo and cro market generated a revenue of USD 3,840.3 million in 2023 and is expected to reach USD 6,632.0 million by 2030.
- The India market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, mammalian was the largest revenue generating source in 2023.
- Non-mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
Biopharmaceutical cmo and cro market data book summary
| Market revenue in 2023 | USD 3,840.3 million |
| Market revenue in 2030 | USD 6,632.0 million |
| Growth rate | 7.8% (CAGR from 2024 to 2030) |
| Largest segment | Mammalian |
| Fastest growing segment | Non-mammalian |
| Historical data | 2017 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Mammalian, Non-mammalian |
| Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
Other key industry trends
- In terms of revenue, India accounted for 10.6% of the global biopharmaceutical cmo and cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, India biopharmaceutical cmo and cro market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 6,632.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biopharmaceutical CMO And CRO Market Scope
Biopharmaceutical CMO And CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Binex | View profile | 101-250 | Torrance, California, United States, North America | https://www.binexline.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Probiogen | View profile | 251-500 | Berlin, Berlin, Germany, Europe | http://www.probiogen.de |
| JRS Pharma | View profile | 11-50 | Rosenberg, Baden-Wurttemberg, Germany, Europe | http://jrspharma.com |
| Innovent Biologics Inc | View profile | 4872 | 168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, China, People's Republic of, 215123 | https://www.innoventbio.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.parexel.com |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | https://www.rentschler-biopharma.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| AGC Inc | View profile | 61671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | https://www.agc.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Toyobo Co Ltd | View profile | 12460 | 2-8, Dojima Hama 2-chome, Kita-ku, Osaka, Japan, 530-8230 | http://www.toyobo.co.jp |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| R1 RCM Inc | View profile | 30000 | 434 West Ascension Way, 6th Floor, Murray, UT, United States, 84123 | https://www.r1rcm.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
India biopharmaceutical cmo and cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 62.08% in 2023. Horizon Databook has segmented the India biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
Indian biopharmaceutical contract manufacturing is rapidly growing due to presence of low-cost manufacturing facilities & production facilities approved by WHO-GMP and patent expiration of drugs. Cost-effectiveness is one of the major advantages offered by Indian CMOs & CROs. Manufacturing cost in India is nearly 30% to 40% lower than that in the U.S. or Europe.
Lower manufacturing cost can be attributed to lower capital & equipment expenses that lead to lower costs of depreciation & interest. Moreover, cost of labor is 50% to 60% lower as compared to Western countries. These factors are attracting significant number of customers from different parts of the world. In addition, rising R&D in India is expected to drive the market in the country.
Reasons to subscribe to India biopharmaceutical cmo and cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India biopharmaceutical cmo and cro market databook
-
Our clientele includes a mix of biopharmaceutical cmo and cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India biopharmaceutical cmo and cro market , including forecasts for subscribers. This country databook contains high-level insights into India biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
India biopharmaceutical cmo and cro market size, by source, 2017-2030 (US$M)
India Biopharmaceutical CMO And CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
